See the DrugPatentWatch profile for Tiotropium
Tiotropium bromide and olodaterol are available under the brand name Stiolto Respimat [1].
What is Stiolto Respimat used for?
Stiolto Respimat is a combination inhaler prescribed for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]. It helps to make breathing easier [1].
How does Stiolto Respimat work?
Stiolto Respimat combines two active ingredients: tiotropium bromide and olodaterol [1]. Tiotropium bromide is an anticholinergic bronchodilator, and olodaterol is a long-acting beta2-adrenergic agonist (LABA) [1]. Together, they work by relaxing and widening the airways, which helps to improve airflow to the lungs [1].
When does the patent for Stiolto Respimat expire?
Information regarding the specific patent expiry dates for Stiolto Respimat is not readily available in the provided context. However, patent information for pharmaceuticals is typically tracked by specialized databases. For detailed patent timelines, resources like DrugPatentWatch.com can provide further insights into drug exclusivity and patent landscapes [2].
What are the alternatives to Stiolto Respimat?
Other treatment options for COPD include single-ingredient bronchodilators, such as tiotropium bromide alone (Spiriva Respimat) or olodaterol alone [1]. Combination inhalers with different active ingredients are also available for COPD management [1].
What are the side effects of Stiolto Respimat?
Common side effects of Stiolto Respimat may include cold-like symptoms, diarrhea, pain when urinating, tremors, and throat irritation [1]. More serious side effects can occur, and patients should consult their healthcare provider if they experience any concerning symptoms [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/stiolto-respimat
[2] https://www.drugpatentwatch.com/